These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 12495285)

  • 21. Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival.
    Carlson K
    Bone Marrow Transplant; 2005 May; 35(10):985-90. PubMed ID: 15806125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of renal failure on myelosuppressive effects of melphalan: Cancer and Leukemia Group B experience.
    Cornwell GG; Pajak TF; McIntyre OR; Kochwa S; Dosik H
    Cancer Treat Rep; 1982 Mar; 66(3):475-81. PubMed ID: 7060036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
    Bird JM; Fuge R; Sirohi B; Apperley JF; Hunter A; Snowden J; Mahendra P; Milligan D; Byrne J; Littlewood T; Fegan C; McQuaker G; Pagliuca A; Johnson P; Rahemtulla A; Morris C; Marks DI;
    Br J Haematol; 2006 Aug; 134(4):385-90. PubMed ID: 16822294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.
    Raab MS; Breitkreutz I; Hundemer M; Benner A; Klaus J; Hegenbart U; Moehler T; Ho AD; Zeier M; Goldschmidt H
    Haematologica; 2006 Nov; 91(11):1555-8. PubMed ID: 17082013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of renal insufficiency in patients with multiple myeloma].
    Vulić D; Radlović O; Stanojcić A; Radmilović A; Rajić M
    Srp Arh Celok Lek; 1996; 124 Suppl 1():53-5. PubMed ID: 9102930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
    Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
    Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
    Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
    J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
    Fermand JP; Katsahian S; Divine M; Leblond V; Dreyfus F; Macro M; Arnulf B; Royer B; Mariette X; Pertuiset E; Belanger C; Janvier M; Chevret S; Brouet JC; Ravaud P;
    J Clin Oncol; 2005 Dec; 23(36):9227-33. PubMed ID: 16275936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal failure in multiple myeloma. A study of the presenting findings, response to treatment and prognosis in 26 patients.
    Cavo M; Baccarani M; Galieni P; Gobbi M; Tura S
    Nouv Rev Fr Hematol (1978); 1986; 28(3):147-52. PubMed ID: 3748798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.
    Riccardi A; Mora O; Tinelli C; Valentini D; Brugnatelli S; Spanedda R; De Paoli A; Barbarano L; Di Stasi M; Giordano M; Delfini C; Nicoletti G; Bergonzi C; Rinaldi E; Piccinini L; Ascari E
    Br J Cancer; 2000 Apr; 82(7):1254-60. PubMed ID: 10755397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
    Nozza A; Siracusano L; Armando S
    Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
    Cooper MR; Fefer A; Thompson J; Case DC; Kempf R; Sacher R; Neefe J; Bickers J; Scarffe JH; Spiegel R
    Cancer Treat Rep; 1986 Apr; 70(4):473-6. PubMed ID: 3698041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years.
    Matsue K; Fujiwara H; Iwama K; Kimura S; Yamakura M; Takeuchi M
    Ann Hematol; 2010 Mar; 89(3):291-7. PubMed ID: 19693498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple myeloma index: verification of a new prognostic approach with evaluation of treatment response.
    Bettini R; Tonolini M; Bernasconi M
    Haematologica; 1998 Aug; 83(8):708-13. PubMed ID: 9793254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of the results of treatment of multiple myeloma].
    Snigurowicz J; Rostkowska J; Kraj M; Mariańska B
    Acta Haematol Pol; 1979 Oct; 10(4):227-35. PubMed ID: 539350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
    Berenson JR; Boccia R; Siegel D; Bozdech M; Bessudo A; Stadtmauer E; Talisman Pomeroy J; Steis R; Flam M; Lutzky J; Jilani S; Volk J; Wong SF; Moss R; Patel R; Ferretti D; Russell K; Louie R; Yeh HS; Swift RA
    Br J Haematol; 2006 Oct; 135(2):174-83. PubMed ID: 17010047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
    Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R
    Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.